What It Is
GHRP-6, or growth hormone-releasing peptide-6, is a synthetic hexapeptide -- a chain of six amino acids -- studied for its ability to trigger growth hormone (GH) release.[1] It belongs to a class of compounds called GH secretagogues, which work differently from recombinant human growth hormone (somatropin): rather than replacing GH directly, GHRP-6 is designed to stimulate the body's own pituitary gland to release it.[6]
GHRP-6 is a research compound. It has no FDA-approved prescribing information, labeled indication, or approved dosage for medical treatment in the United States.[3]
How It Works
GHRP-6 activates the growth hormone secretagogue receptor (GHS-R), which was identified in the pituitary and hypothalamus before its natural ligand, the hunger-related hormone ghrelin, was isolated from the stomach.[2][5] Activating this receptor prompts the pituitary gland to release GH, and GHRP-6 can amplify that effect further when studied alongside growth hormone-releasing hormone (GHRH), since the two act through partly distinct but complementary pathways.[6][7]
Because GHRP-6 works through the same receptor family as ghrelin, it also shares ghrelin's connection to appetite and feeding behavior, which is why hunger is one of the more consistently reported effects in GHRP-6 research.[10] Activating a GH-release switch is not the same as proving a downstream health benefit; that requires controlled outcome studies in defined populations.
What the Research Shows
Human research on GHRP-6 is best described as early clinical physiology work rather than outcome-focused trials. Older studies examined whether GHRP-6 could stimulate GH secretion, how that response changed with age, obesity, or co-administration of GHRH, and how it compared with related secretagogues -- but these were largely small, short-term studies built around hormone sampling, not patient-centered endpoints like strength, body composition, or recovery.[6][7]
Preclinical work, including the original receptor-cloning studies and animal models of ghrelin biology, supports the mechanism but cannot establish human benefit. Claims commonly seen online -- that GHRP-6 builds muscle, reverses aging, improves recovery, or has minimal side effects -- go well beyond what any published study has demonstrated. For comparison, a different oral GH secretagogue, macimorelin, does have FDA-approved labeling, but only for diagnosing adult growth hormone deficiency in a clinical setting; that approval does not extend to GHRP-6.[12]
Safety & Side Effects
Because GHRP-6 has no FDA-approved label, there is no formal adverse-reaction table to draw from. Effects reported in the research literature include:
- Hunger, a plausible and frequently noted effect tied to ghrelin-receptor activity[10]
- Flushing and transient fatigue in some study contexts[6][7]
- Changes in cortisol, prolactin, insulin, or glucose, depending on dose and individual factors[6][7]
GH-axis manipulation is not a minor wellness intervention; it intersects with glucose metabolism and endocrine test interpretation. People with pituitary disorders, active cancer, uncontrolled diabetes, or who are pregnant or breastfeeding should treat GH secretagogues as medically significant and avoid self-directed use, given how little GHRP-6-specific safety data exists for these groups.[11]
Regulatory Status
GHRP-6 is not FDA-approved for any medical use in the United States and does not appear in FDA drug-approval databases such as Drugs@FDA or the Orange Book.[3][4] Compounded or "research-grade" GHRP-6 products are not reviewed by FDA for safety, effectiveness, or quality before reaching the market, which creates identity, purity, and sterility risks separate from any biological question about the peptide itself.[8][9]
Athletes should also note that growth hormone secretagogues, including GHRP-6, fall under the World Anti-Doping Agency's Prohibited List, making them a banned category in most competitive sport regardless of their unapproved status in ordinary medical use.[16]